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Abstract 
 
Background: Total hip (THA) and knee (TKA) arthroplasty are common orthopaedic procedures most 
frequently for older people. Whilst it is known that this older population frequently present with medical 
morbidities, no studies have previously documented the prevalence of such morbidities in people who have 
undergone THA or TKA. The purpose of this study was to determine the prevalence and what factors are in 
association with the presentation of medical morbidities in these populations.  
 
Methods: Data from the Osteoarthritis Initiative, a population-based observational study, was assessed. In total 
419 people who had undergone a THA or TKA were assessed to determine the prevalence of recorded 
morbidities within 12 months post-arthroplasty.  All medical morbidities were then assessed using univariate 
and then multivariate logistic regression analysis to identify factors influencing the presentation of specific 
morbidities at 12 months following THA or TKA. 
 
Results: The most common medical morbidities included: osteoporosis (16%), mild to moderate depression 
(8%), cancer (8%), diabetes (6%), history of stroke or TIA (6%) and asthma (5%). The medical morbidities 
demonstrated are similar between those who undergo THA and TKA.  Only gender and ethnic origin were 
identified as statistically significant predictors of medical morbidities in these populations. Gender was a 
predictor of history of heart failure, whilst ethnic origin significantly predicted depression. 
 
Conclusions: People who undergo THA or TKA may present with a variety of medical morbidities. 
Accordingly consideration should be made on how to encourage the adoption and maintenance of physical 
activity and healthy lifestyle choices for this population.  
Keywords: Medical multi-morbidities; joint replacement; orthopaedic; osteoarthritis; older people 
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Introduction 
 
Osteoarthritis is one of the most common musculoskeletal diseases worldwide with a prevalence of 20% to 30% 
[1]. It is associated with pain, stiffness, reduced independence and a reduced quality of life [2]. End-stage 
surgical management for osteoarthritis is arthroplasty [3]. Total hip (THA) and knee arthroplasty (TKA) are the 
most common forms of arthroplasty for osteoarthritis [4]. A total of 99,575 THAs and 104,378 TKAs were 
performed in England, Wales and Northern Ireland alone in 2014 [4]. 
 
People who undergo arthroplasty commonly present with medical morbidities [4] due to age as well as lifestyle 
choice, mirroring the normal population [5-7]. These morbidities can have an impact not only on people’s 
recovery following major surgery, but also on their capabilities to engage in physical activity post-arthroplasty. 
A recent systematic review has identified that people following arthroplasty either return to their pre-surgical 
levels of physical activity, or a lower level of physical activity following THA or TKA [8]. This may be due to a 
number of reasons. One such reason has been attributed to pre-existing medical morbidities. Harding et al [9] in 
their qualitative study reported that people post-TKA adopted new reasons for not engaging in physical activity 
and exercise, with a recurrent ‘new limitation’ being cardiovascular disease and other non-communicable 
diseases. 
Whilst it is known that this population frequently present with medical morbidities, no studies have previously 
documented the prevalence of such morbidities in people who have undergone THA or TKA. Furthermore, no 
studies have explored the existence of predictors for specific medical morbidities in this population. Such 
analyses would provide valuable insights to determine the overall health of this population, and whether medical 
morbidities should be considered when designing rehabilitation programmes following THA and TKA. Given 
this, the purpose of this study was to answer the following research questions: what are the most common 
medical morbidities in people who have recently had THA or TKA, and what factors influence the presentation 
of specific morbidities.  
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Methods 
Osteoarthritis Initiative Dataset 
Data used in the preparation of this article was obtained from the Osteoarthritis Initiative (OAI) database, which 
is available for public access at http://www.oai.ucsf.edu/. The OAI is a large-scale, multi-centre (four sites 
across the USA), longitudinal cohort study aimed to investigate the role of biomarkers in the development and 
progression of lower limb osteoarthritis.  
Baseline data collected between February 2004 and May 2006. Data has been collected longitudinally at 12, 24, 
30, 36, 48, 60, 72 and 84 months post-baseline. Data collected includes individual's demographic characteristics, 
previous and current medical history including medical morbidities, . For this analysis, data were identified from 
all datasets from baseline to 84 month follow-up with the exception of Month 30 data-point since this did not 
present morbidity data. 
 
Cohort 
The cohort of interest was people who had undergone THA or TKA in the previous 12 months with the aim to 
ascertain which medical morbidities people who had undergone arthroplasty initially presented within 12 
months post-operatively. The morbidities for all people who had undergone THA or TKA were included. Since 
this study was interested in individual’s health status rather than arthroplasty per se, where people had 
undergone multiple arthroplasty procedures within the OAI follow-up period, we only analysed the morbidities 
recorded within the first 12 months of their first arthroplasty procedure to avoid multiplicity of data. 
Outcomes 
 
The outcomes of interest were self-reported medical conditions which included: osteoporosis, history of 
myocardial infarction, heart failure, deep vein thrombosis, liver failure, stroke or transient ischaemic attack 
(TIA), dementia, asthma, chronic obstructive pulmonary disease (COPD), gastric ulcer, diabetes, kidney failure, 
cancer (any type), psoriasis, Crohn’s diseases or ulcerative colitis, rheumatoid arthritis, polymyalgia rheumatica, 
gout, psoriatic arthritis, ankylosing spondylitis and depression (diagnosed with the Center for Epidemiologic 
Studies Depression (CES-D) scale) with the thresholds: less than 15 no depression; 15-21 mild to moderate 
depression; over 21 possibility of major depression [10]. In addition to these individual conditions, data on the 
Charlson Comorbidity Index, a valid and reliable tool used to predict mortality by classifying 19 comorbidities 
[11], was also collected.  
 
Data analysis 
The prevalence of each medical morbidity was determined with 95% confidence intervals (CI). All medical 
morbidities were then assessed using univariate logistic regression analysis to identify factors influencing their 
presentation. The dependent variables were the presence of the following self-reported morbidities: 
osteoporosis, history of myocardial infarct, heart failure, deep vein thrombosis, liver failure, stroke or TIA, 
dementia, asthma, COPD, gastric ulcer, diabetes, kidney failure, cancer (any), psoriasis, Crohn’s diseases or 
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ulcerative colitis, rheumatoid arthritis, polymyalgia rheumatica, gout, psoriatic arthritis, ankylosing spondylitis 
and depression. Independent variables identified through previous research as potential explanatory factors 
included: age at arthroplasty, gender, ethnic origin, height and weight and arthroplasty procedure (THA or 
TKA). Based on these, all variables identified as significant at p<0.1 on univariate analysis were entered into a 
multivariate logistical regression model. All logistical regression data was expressed as odd ratios (OR) with 
95% CI and p-values. The Wald statistic was used to assess statistical significance in each regression model. All 
analyses were undertaken using STATA version 12.0 (STATACorp LP, Texas, USA). 
 
Ethics approval 
Committee on Human Research, University of California, San Francisco (IRB approval number 10-00532 
Approved 10th March 2015).  
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Results 
Figure 1 illustrates the subject selection based on the a priori eligibility criteria. In total, 419 individuals were 
included in the analysis (110 THA/309 TKA). The demographic characteristics of the cohort are presented in 
Table 1.  Mean age was 69.3 years (67.7 THA/69.9 TKA).  The cohort consisted of 172 males and 247 females. 
In the THA cohort, gender composition was 50 males and 60 females. In the TKA cohort this was 122 males 
and 187 females. The most predominant ethnic group were Caucasians (81.4% of the total cohort). Mean 
maximum adult weight reported was 88.4 kg (87.8 kg THA/88.6 kg TKA). Mean minimum adult weight 
reported was 62.3 kg (63.8 kg THA/61.7 kg TKA). 
  
Prevalence of morbidities 
  
A summary of the prevalence values and confidence intervals for each of the reported medical morbidity is 
presented in Table 2. The most prevalent medical morbidity was osteoporosis (15.5%; 10.0% THA/17.5% 
TKA).  After this, the most common morbidities were mild to moderate depression (8.4%; 10.0% THA/7.8% 
TKA), a history of cancer (any type; 8.1% total; 8.1% THA/8.1% TKA), diabetes (5.7%; 6.4% THA/5.5% 
TKA) and a history of stroke or TIA (5.5%; 4.8% THA/5.7% TKA). The prevalence for cardiac and respiratory 
morbidities was lower for a history of myocardial infarct (3.7% total; 6.5% THA/2.9% TKA),  a history of heart 
failure (3.0% total: 0.0% THA; 3.8% TKA), asthma (4.8% total; 4.6% THA/4.9% TKA), and COPD (3.0% 
total; 4.8% THA/2.4% TKA).  
  
There was a low prevalence for morbidities such as dementia (0.0% total and THA/TKA), Crohn’s disease or 
ulcerative colitis (0.1%; 0.9% THA/0.0% TKA), psoriatic arthritis (0.1%; 0.0% THA; 0.3% TKA), polymyalgia 
rheumatic (0.5%; 0.0% THA/0.7% TKA) and ankylosing spondylitis (0.6%; 1.8% THA/0.3% TKA). 
 
Mean Charlson Co-morbidity Index was 0.57 (standard deviation (SD): 0.97) for the total cohort, 0.56 (SD: 
0.93) for THA and 0.57 (SD: 0.98) for TKA. Forty-three people (10.3%) presented with two or more 
morbidities in the total cohort (THA: n=10 (9%); TKA: n=33 (10.7%)).  
 
Predictors of medical morbidities 
  
Table 3 presents the results of the logistical regression analysis. As this demonstrates, there were significant 
predictors for nine morbidities (history of myocardial infarct; history of heart failure; asthma; diabetes; history 
of kidney failure; history of cancer (any type); rheumatoid arthritis; gout; depression). The most frequently 
identified predictor characteristic was maximum adult weight. This was a significant predictor for: a history of 
heart failure (OR: 1.04; 95% CI: 1.00-1.09), history of kidney failure (OR: 1.07; 95% CI: 1.02-1.13), history of 
cancer (any type) (OR: 1.03; 95% CI: 1.01-1.06) and rheumatoid arthritis (OR: 0.97; 95% CI: 0.93-1.00). With 
the exception of rheumatoid arthritis, the higher the maximum adult weight, the greater likelihood of 
experiencing these morbidities. Conversely, minimum adult weight was a significant predictor for asthma (OR: 
0.95; 95% CI: 0.90-1.00), history of cancer (any type) (OR: 1.04; 95% CI: 1.01-1.08) and gout (OR: 1.05; 95% 
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CI: 0.99-1.10). With the exception of asthma, the higher the minimum adult weight, the greater the likelihood of 
experiencing these morbidities. Mean weight at 25 years of age was a significant predictor of history of cancer 
(any type) (OR: 1.04; 95% CI: 1.01-1.07) and gout (OR: 1.05; 95% CI: 1.00-1.05). Higher weight equated to 
greater the likelihood of experiencing these morbidities.  Mean height at 25 years of age was associated with a 
history of heart failure (OR: 1.01; 95% CI: 1.00-1.02) with greater height associated with greater likelihood of 
experiencing this morbidity.  
  
Gender was identified as a significant predictor for a history of myocardial infarct (OR: 6.24; 95% CI: 1.30-
29.95), a history of heart failure (OR: 4.59; 95% CI: 0.91-23.16) and a history of cancer (any type) (OR: 2.26; 
95% CI: 0.93-5.50), where males were more likely to experience these morbidities. Ethnic origin was identified 
as a significant predictor for diabetes (OR: 2.11; 95% CI: 0.95-4.65). However, when analysed individually, 
none of the categories of race were identified as specific predictors. Age at arthroplasty was only a predictor for 
depression (based on CES-D thresholds (OR: 0.97; 95% CI: 0.94-1.01); where lower age was associated with a 
greater likelihood of depression. The type of joint replacement received i.e. THA or TKA, was not identified as 
a predictor in this dataset. 
 
The findings of the multivariate logistical regression model are presented in Supplementary Table 1. This 
indicated that only gender, ethnic origin and mean weight at aged 25 years were significant predictors of 
morbidities. The model indicated that males were 0.21 times at lower likelihood of having a history of heart 
failure compared to females (OR: 0.21; 95% CI: 0.94-23.95). Ethnic origin was a significant predictor overall 
for experiencing depression (OR: 3.58; 95% CI: 1.92-6.66). However when assessed by categorising individual 
ethnic groups, there was no statistically significant difference in predictive values between Caucasian, African-
American or Asian groups (p=0.99). Finally mean weight at aged 25 was a statistically significant predictor of 
gout, where an increase of one kilogram was associated with an increased likelihood of experiencing gout by 0.1 
times (OR: 1.05; 95% CI: 1.00-1.10). 
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Discussion 
The findings of this study indicate that people who undergo THA or TKA present with a number of important 
morbidities. The morbidities demonstrated were similar between those who underwent a THA or TKA. The 
most common morbidities included: osteoporosis, mild to moderate depression, cancer, diabetes, history of 
stroke or TIA and asthma. Medical morbidities which least frequently present in this population include 
dementia, Crohn’s disease, polymyalgia and psoriatic arthritis. Only gender and ethnic origin were identified as 
statistically significant predictors of morbidities, with gender a predictor of history of heart failure, whilst ethnic 
origin significantly predicted depression. 
This study is the first paper to identify what specific morbidities people following THA and TKA present with. 
The results suggest that the most common medical co-morbidities are non-communicable diseases. Morbidities 
such as osteoporosis, depression, cancer, diabetes, and stroke/TIA are all diseases frequently seen within this 
age group in the normative population and non-arthroplasty cohorts [5-7], where mean age for a hip and knee 
arthroplasty is 70 years [4]. This paper is therefore valuable as it provides an insight into possible morbidities 
which may influence rehabilitation and recovery [12]. These diseases could have a detrimental effect on post-
operative outcome, potentially increasing risks of complications such as wound infections and reduced exercise 
capability, both in the short- and longer-term post-THA and TKA [13,14]. This should be considered when 
designing generic rehabilitation pathways, accounting for these possible conditions, providing the flexibility to 
adapt progression based on these morbidities’ physiological impact. 
A secondary value of this analysis was that we have identified potential predictors for these morbidities in this 
population. On univariate analysis, weight at age 25 years and maximum weight were identified as recurrent 
significant predictors. Whilst these were not supported on multivariate analysis, previous studies have also 
identified the importance of these factors [15]. It is widely recognised that weight management programmes are 
an important component for the non-surgical management of hip and knee osteoarthritis [16]. This data would 
therefore further support this, providing added rationale for the potential benefit that weight management for 
this post-arthroplasty cohort, could have on reducing the associated risks with these morbidities.  
The type of arthroplasty undergone (THA or TKA) was not a significant predictor of morbidity. This suggests 
homogeneity in the co-existing medical conditions experienced by these populations. Thus, when generic 
rehabilitation programmes are designed and delivered following THA and TKA, consideration on the 
underlying morbidities this population present should not be a distinguishing factor between regimes. 
Consequently, the rehabilitation needs for this population in terms of muscle strength, loss of range of motion, 
gait re-education and improving balance and functional performance [17] should be the primary concern for 
each cohort. 
Previous research has identified that a patients’ physical activity either maintains at a pre-surgical levels or 
reduces following THA or TKA. The burden on individuals in this study, their families and health services, of 
the most commonly identified morbidities can be reduced through the adoption of physical activity and lifestyle 
programmes. Previous research has provided a rigorous evidence-base in support of the adoption of physical 
activity strategies in the management of osteoporosis [18], depression [19], diabetes [20] and asthma [21]. 
However encouraging and maintaining physical activity programmes in this population has been highlighted as 
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challenging, particularly for long term-adherence [8]. Given the encouragement to adopt a ‘making-every-
contact-count’ approach to health promotion [22], clinicians such as orthopaedic surgeons, physiotherapists, 
occupational therapists, community nurses and general practitioners could have a significant role in highlighting 
the threat of these morbidities within routine follow-up consultations post-arthroplasty. Further research is 
warranted on strategies to target such morbidities to improve both the physical and mental health of this 
population, given the potential beneficial impact these could have on long-term primary and secondary care 
management. 
This study presented with three limitations. The data of medical morbidities derived from the OAI dataset was 
self-reported. Consequently, the morbidities reported may have been influenced by systematic errors through 
individual’s capability to recall medical history. Secondly the OAI dataset identified morbidities which where a 
priori defined as important. Therefore these individuals may have presented with other morbidities which were 
not assessed as part of the data collection process. Nonetheless, the morbidities recorded are those most 
frequently reported in previous non-arthroplasty cohorts with comparable age and sex-matched characteristics 
[5-7]. Also the Charlson Co-morbidity Index was low (total cohort mean: 0.57) suggesting that the reported 
morbidities were potentially attributable to the morbidities reported. Finally, the OAI database is a cohort of 
individuals from North America. Whilst this providers valuable data, there may be limited generalisability to 
other continents such as Asia, Africa and Europe. Further validation work may, therefore, be warranted to 
ascertain how these findings relate to other nationalities before considering the translation of these results into 
public health strategies.  
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Figure and Table Legends 
 
Figure 1: Flow-chart illustrating the subject selection based on a priori eligibility criteria.  
Table 1: Demographic characteristics 
Table 2: Frequency of morbidities (overall and by arthroplasty) 
Table 3: Result of the univariate logistical regression analysis (OR, 95% confidence interval; p-values) for 
predicting specific morbidities. 
Supplementary Table 1. Multivariate logistic regression analysis (OR, 95% confidence interval; p-values for 
predictors and p-values for non-predictors) for predicting specific morbidities identified as significant on 
univariate analysis. 
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Figure 1: Flow-chart illustrating the subject selection based on a priori eligibility criteria. 
 
 
 
Total OAI dataset 
(N=4796) 
THA or TKA datasets 
(N=487) 
Individual THA or TKA 
participants  
(N=419) 
Individual THA 
participants  
(N=110) 
Non-THA/TKA datasets 
(N=4309) 
Individuals with second joint THA 
& TKA 
(N=68) 
Individual TKA 
participants  
(N=309) 
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Table 1: Demographic characteristics 
 Total Cohort THA TKA 
N 419 110 309 
Mean age at arthroplasty in years (SD) 69.3 (26.9) 67.7 (9.4) 69.9 (31.0) 
Gender (m/f) 172/247 50/60 122/187 
Race    
      Non-white 8 2 0 
      Caucasian 341 93 248 
      African-American 66 14 52 
      Asian 4 1 3 
Mean height at aged 25 in meters (SD) 1.65 (0.26) 1.65 (0.29) 1.65 (0.25) 
Mean weight at aged 25 in kg (SD) 67.8 (13.0) 69.1 (13.2) 67.3 (13.0) 
Maximum adult weight in kg (SD) 88.4 (16.2) 87.8 (14.4) 88.6 (16.9) 
Minimum adult weight in kg (SD) 62.3 (11.3) 63.8 (11.6) 61.7 (11.3) 
F – female; kg- kilograms; M – Males; N – number; SD – standard deviation; THA – total hip arthroplasty;  
TKR – total knee arthroplasty
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Table 2: Frequency of morbidities (overall and by arthroplasty) 
Frequency of morbidities Total Cohort (N=419) THA (N=110) TKA (N=309) 
Frequency Prevalence (%) 
(95% CI) 
Frequency Prevalence (%)  
(95% CI) 
Frequency Prevalence (%)  
(95% CI) 
Osteoporosis 65/419 15.5 (12.4-19.3) 11/110 10.0 (5.7-17.0) 54/309 17.5 (13.7-22.1) 
History of myocardial infarct 10/271 3.7 (2.0-6.7) 4/62 6.5 (2.5-15.5) 6/209 2.9 (1.3-6.1) 
History of heart failure 8/271 3.0 (1.5-5.7) 0/62 0.0 (0.0-0.0) 8/209 3.8 (2.0-7.4) 
History of deep vein thrombosis or PE 4/274 1.5 (0.6-3.7) 0/62 0.0 (0.0-0.0) 4/209 1.9 (0.7-4.8) 
History of liver failure 4/271 1.5 (0.6-3.7) 0/62 0.0 (0.0-0.0) 4/209 1.9 (0.7-4.8) 
History of Stroke or TIA 15/271 5.5 (3.4-8.9) 3/62 4.8 (1.7-13.3) 12/209 5.7 (3.3-9.8) 
Dementia 0/419 0.0 (0.0-0.0) 0/110 0.0 (0.0-0.0) 0/309 0.0 (0.0-0.0) 
Asthma 20/419 4.8 (3.1-7.3) 5/110 4.6 (2.0-10.2) 15/309 4.9 (3.0-7.9) 
COPD 8/271 3.0 (1.5-5.7) 3/62 4.8 (1.7-13.3) 5/209 2.4 (0.1-5.5) 
Diabetes 24/419 5.7 (3.9-8.4) 7/110 6.4 (3.1-12.6) 17/309 5.5 (3.5-8.6) 
History of kidney failure 7/271 2.6 (1.3-5.2) 2/62 3.2 (0.9-11.0) 5/209 2.4 (1.0-5.5) 
History of cancer (any) 22/271 8.1 (5.4-12.0) 5/62 8.1 (3.5-17.5) 17/209 8.1 (5.1-12.6) 
Psoriasis 11/419 2.6 (1.5-4.7) 1/110 0.9 (0.2-5.0) 10/309 3.2 (1.8-5.9) 
History of Crohn’s diseases or ulcerative colitis 1/419 0.1 (0.0-1.1) 1/110 0.9 (0.2-5.0) 0/309 0.0 (0.0-0.0) 
Rheumatoid arthritis 12/419 2.9 (1.6-4.9) 1/110 0.9 (0.2-5.0) 11/309 3.6 (2.0-6.3) 
Polymyalgia rheumatica 2/419 0.5 (0.1-1.7) 0/110 0.0 (0.0-0.0) 2/309 0.7 (0.2-2.3) 
Gout 9/419 2.8 (1.1-4.0) 2/110 1.8 (0.5-6.4) 7/309 2.3 (1.1-4.6) 
Psoriatic arthritis 1/419 0.1 (0.0-1.1) 0/110 0.0 (0.0-0.0) 1/309 0.3 (0.1-0.2) 
Ankylosing spondylitis 3/419 0.6 (0.0-2.1) 2/110 1.8 (0.5-6.4) 1/309 0.3 (0.1-0.2) 
Depression (based on CES-D thresholds) 
No depression 368/419 87.8 (84.4-90.6) 94/110 85.5 (77.7-90.8) 274/309 88.7 (84.7-91.7) 
Mild to moderate depression 35/419 8.4 (6.1-11.4) 11/110 10.0 (5.7-17.0) 24/309 7.8 (5.3-11.3) 
Possible major depression 15/419 3.6 (2.2-5.8) 4/110 3.6 (1.4-9.0) 11/309 3.6 (2.0-6.3) 
Mean CES-D score (SD) 6.94 (6.68) N/E 7.64 (8.01) N/E 6.72 (6.13) N/E 
Mean Charlson Comorbidity Index (SD) 0.57 (0.97) N/E 0.56 (0.93) N/E 0.57 (0.98) N/E 
CES-D - Center for Epidemiologic Studies Depression; CI – confidence interval; COPD – chronic obstructive pulmonary disease; N/E – not estimable; PE – pulmonary 
embolism; SD – standard deviation; THA – total hip arthroplasty; TIA - transient ischaemic attack; TKA – total knee arthroplasty.  
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Table 3: Result of the univariate logistical regression analysis (OR, 95% confidence interval; p-values) for predicting specific morbidities. 
 Mean age at 
arthroplasty  
Gender 
(male:female) 
Ethnic origin Mean height 
at aged 25 
Mean weight 
at aged 25  
Maximum 
adult weight  
Minimum 
adult weight 
Type of 
Arthroplasty 
Osteoporosis 0.98 (0.94-
1.01; 0.19) 
1.18 (0.66-2.11; 
0.57) 
0.31 (0.05-
1.93; 0.21) 
1.00 (1.00-
1.00; 0.59) 
1.00 (0.05-
3.49; 0.88) 
0.99 (0.94-
1.01; 0.32) 
0.99 (0.97-
1.00; 0.22) 
0.84 (0.46-
1.58; 0.60) 
History of myocardial infarct 0.95 (0.84-
1.07; 0.42) 
6.24 (1.30-
29.95; 0.02)  
0.31 (0.04-
2.37; 0.26) 
1.00 (0.99-
1.01; 0.86) 
1.00 (0.00-
0.00; 1.00) 
1.03 (0.99-
1.08; 0.19) 
1.02 (0.98-
1.06; 0.30) 
0.43 (0.12-
1.57; 0.20) 
History of heart failure 0.99 (0.87-
1.11; 0.80) 
4.59 (0.91-
23.16; 0.07)  
1.44 (0.20-
10.27; 0.72) 
1.01 (1.00-
1.02; 0.08)  
1.03 (0.99-
1.09; 0.17) 
1.04 (1.00-
1.09; 0.09)  
1.05 (0.99-
1.10; 0.12) 
0.00 (0.00-
0.00; 1.00) 
History of deep vein thrombosis 
or PE 
1.00 (0.98-
1.03; 0.87) 
1.47 (0.20-
10.61; 0.70) 
1.44 (0.20-
10.27; 0.72) 
1.00 (0.99-
1.01; 0.59) 
1.01 (0.94-
1.08; 0.87) 
1.02 (0.96-
1.08; 0.61) 
1.01 (0.93-
1.09; 0.86) 
0.00 (0.00-
0.00; 1.00) 
History of liver failure 0.92 (0.78-
1.10; 0.37) 
0.48 (0.05-4.71; 
0.53) 
1.17 (0.38-
3.55; 0.79) 
1.00 (0.98-
1.01; 0.30) 
0.93 (0.84-
1.04; 0.23) 
0.98 (0.92-
1.04; 0.53) 
0.93 (0.82-
1.04; 0.21) 
0.00 (0.00-
0.00; 1.00) 
History of Stroke or TIA 1.00 (0.98-
1.02; 0.99) 
1.30 (0.46-3.70; 
0.62) 
1.17 (0.39-
3.55; 0.79) 
1.00 (1.00-
1.00; 0.96) 
1.00 (0.96-
1.04; 0.97) 
1.01 (0.97-
1.04; 0.71) 
1.00 (0.96-
1.05; 0.94) 
0.84 (0.23-
3.06; 0.79) 
Dementia 0.99 (0.97-
1.01; 0.45) 
0.87 (0.58-1.31; 
0.51) 
0.93 (0.59-
1.48; 0.77) 
1.00 (1.00-
1.00; 0.70) 
1.00 (1.00-
1.02; 0.58) 
1.00 (0.99-
1.01; 0.67) 
1.00 (0.99-
1.02; 0.77) 
1.09 (0.69-
1.70; 0.72) 
Asthma 0.98 (0.92-
1.03; 0.42) 
0.61 (0.23-1.63; 
0.32) 
1.48 (0.59-
3.70; 0.41) 
1.00 (0.99-
1.00; 0.25) 
0.97 (0.93-
1.01; 0.13) 
1.00 (0.98-
1.03; 0.83) 
0.95 (0.90-
1.00; 0.03) 
1.14 (0.40-
3.26; 0.82) 
COPD 1.00 (0.98-
1.02; 0.92) 
0.68 (0.17-2.76; 
0.58) 
0.78 (0.14-
4.24; 0.77) 
1.00 (0.99-
1.01; 0.64) 
0.97 (0.91-
1.03; 0.29) 
1.00 (0.96-
1.05; 0.90) 
0.96 (0.89-
1.03; 0.25) 
2.08 (0.48-
8.94; 0.33) 
Diabetes 1.00 (0.98-
1.02; 0.91) 
1.27 (0.55-2.94; 
0.58) 
2.11 (0.95-
4.65; 0.07)  
1.00 (1.00-
1.00; 0.49) 
1.02 (0.99-
1.05; 0.24) 
1.02 (0.99-
1.05; 0.14) 
1.01 (0.97-
1.04; 0.68) 
1.44 (0.57-
3.64; 0.44) 
History of kidney failure 1.00 (0.98-
1.02; 0.92) 
0.50 (0.11-2.29; 
0.38) 
0.31 (0.04-
2.71; 0.29) 
1.00 (1.00-
1.01; 0.18) 
1.03 (0.98-
1.08; 0.31) 
1.07 (1.02-
1.13; 0.01) 
1.02 (0.96-
1.09; 0.47) 
1.36 (0.26-
7.19; 0.72) 
History of cancer (any) 1.00 (0.99-
1.01; 0.84) 
2.26 (0.93-5.50; 
0.07)  
0.83 (0.30-
2.31; 0.72) 
1.00 (1.00-
1.01; 0.16) 
1.04 (1.01-
1.07; 0.02)  
1.03 (1.01-
1.06; 0.02)  
1.04 (1.01-
1.08; 0.02)  
0.99 (0.35-
2.80; 0.99) 
Psoriasis 0.96 (0.89-
1.03; 0.28) 
1.71 (0.51-5.78; 
0.39) 
1.22 (0.32-
4.61; 0.77) 
1.00 (0.99-
1.01; 0.87) 
1.01 (0.97-
1.06; 0.59) 
1.02 (0.98-
1.05; 0.42) 
1.01 (0.96-
1.06; 0.82) 
0.22 (0.03-
1.75; 0.15) 
History of Crohn’s diseases or 
ulcerative colitis 
1.26 (0.82-
1.93; 0.28) 
0.00 (0.00-0.00; 
1.00) 
0.34 (0.01-
108.95; 0.71) 
0.99 (0.96-
1.02; 0.35) 
0.99 (0.85-
1.15; 0.85) 
1.00 (0.89-
1.13; 0.99) 
1.01 (0.85-
1.18; 0.95) 
0.00 (0.00-
0.00; 1.00) 
Rheumatoid arthritis 1.02 (0.99-
1.04; 0.24) 
0.71 (0.21-2.41; 
0.59) 
1.01 (0.27-
3.81; 0.99) 
1.0 (0.99-1.01; 
0.84) 
0.97 (0.92-
1.02; 0.21) 
0.97 (0.93-
1.00; 0.07) 
0.95 (0.90-
1.01; 0.12) 
0.26 (0.03-
2.07; 0.21) 
Polymyalgia rheumatic 1.00 (0.92-
1.08; 0.94) 
0.00 (0.00-0.00; 
1.00) 
0.32 (0.01-
16.62; 0.57) 
0.99 (0.98-
1.01; 0.36) 
0.92 (0.78-
1.09; 0.33) 
1.00 (0.91-
1.09; 0.93) 
0.92 (0.77-
1.09; 0.32) 
0.00 (0.00-
0.00; 1.00) 
Gout 1.00 (0.98- 0.33 (0.08-1.32; 2.03 (0.62- 1.00 (1.00- 1.05 (1.00- 1.03 (0.99- 1.05 (0.99- 0.83 (0.17-
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1.02; 0.95) 0.12) 6.71; 0.25) 1.01; 0.13) 1.10; 0.04) 1.08; 0.13) 1.10; 0.08) 4.08; 0.82) 
Psoriatic arthritis 1.06 (0.84-
1.35; 0.61) 
0.00 (0.00-0.00; 
1.00) 
0.00 (0.00-
0.00; 1.00) 
1.00 (0.98-
1.02; 0.84) 
1.05 (0.91-
1.21; 0.52) 
1.00 (0.89-
1.13; 0.97) 
1.07 (0.91-
1.25; 0.43) 
0.00 (0.00-
0.00; 1.00) 
Ankylosing spondylitis 0.93 (0.81-
1.07; 0.33) 
0.70 (0.06-7.81; 
0.77) 
2.20 (0.28-
17.52; 0.46) 
1.00 (0.98-
1.01; 0.50) 
1.03 (0.95-
1.12; 0.46) 
1.04 (0.97-
1.12; 0.23) 
1.01 (0.92-
1.11; 0.83) 
4.81 (0.43-
54.02; 0.20) 
Depression (based on CES-D 
thresholds) 
0.97 (0.94-
1.01; 0.09)  
0.62 (0.33-1.16; 
0.14) 
3.10 (1.76-
5.47; 0.00)  
1.00 (1.00-
1.00; 0.96) 
1.00 (0.97-
1.02; 0.74) 
1.01 (1.00-
1.03; 0.33) 
0.99 (0.97-
1.02; 0.53) 
1.33 (0.71-
2.52; 0.38) 
CES-D - Center for Epidemiologic Studies Depression; COPD – chronic obstructive pulmonary disease; N/E – not estimable; OR – odds ratio; PE – pulmonary embolism; 
TIA - transient ischaemic attack 
 
 
18 
 
Supplementary Table 1. Multivariate logistic regression analysis (OR, 95% confidence interval; p-values for predictors and p-values for non-predictors) for 
predicting specific morbidities identified as significant on univariate analysis. 
 Mean age at 
arthroplasty  
Gender (males: 
females) 
Ethnic origin Mean height at 
aged 25 
Mean weight at 
aged 25  
Maximum 
adult weight  
Minimum 
adult weight 
Type of 
Arthroplasty 
History of heart failure N/E OR: 0.21 (0.94-
23.95; 0.06)  
N/E 0.55 N/E 0.29 N/E N/E 
History of cancer (any) N/E N/E N/E N/E 0.16 0.08 0.11 N/E 
Gout N/E N/E N/E N/E 1.05 (1.00-1.10; 
0.04)  
N/E 0.99 N/E 
Depression (based on CES-D 
thresholds) 
P=0.51 N/E OR: 3.578 (1.92-
6.66; <0.01) 
N/E N/E N/E N/E N/E 
CES-D - Center for Epidemiologic Studies Depression; COPD – chronic obstructive pulmonary disease; N/E – not estimable; OR – odds ratio; TIA - transient ischaemic 
attack 
 
